Century Therapeutics narrows loss despite 8% post-earnings drop
BMS partnership drives revenue surge to $109.2M as cash runway extends to 2029
Century Therapeutics shares fell 8.4% on Thursday despite the biotechnology company reporting a narrower-than-expected quarterly loss and dramatically improved full-year financial results, in a move analysts attributed to profit-taking following a recent surge in the stock's price.
The Philadelphia-based company, which develops allogenic cell therapies using induced pluripotent stem cell (iPSC) technology, reported a non-GAAP loss per share of $0.25 for the fourth quarter of 2025, beating the consensus estimate of a $0.289 loss, according to market data.
For the full year ended December 31, 2025, Century Therapeutics narrowed its net loss to $9.6 million, a substantial improvement from a net loss of $126.6 million in the prior year. The dramatic turnaround was largely driven by collaboration revenue of $109.2 million from its partnership with Bristol Myers Squibb, compared to $6.6 million in 2024, as reported in the company's financial results.
The company's financial position strengthened considerably, with cash, cash equivalents, and marketable securities totaling $117.1 million as of December 31, 2025. Combined with an oversubscribed $135 million private placement completed in January 2026, Century Therapeutics extended its cash runway into the first quarter of 2029, providing significant operational flexibility as it advances its pipeline of off-the-shelf cancer treatments.
Despite these positive developments, the stock's decline appears to reflect a classic "sell the news" pattern. Century shares had rallied 29% between March 3 and March 9, suggesting investors may have been anticipating strong results and opted to lock in gains following the earnings announcement. The stock now trades at $2.50, giving the company a market capitalization of approximately $239 million.
Analysts maintain a generally positive outlook on the stock, with a consensus target price of $3.50, representing potential upside of about 40% from current levels. Three analysts currently rate the shares a buy or strong buy, while one recommends hold, according to current market data.
The company's iPSC technology platform positions it in the fast-growing cell therapy sector, which aims to develop more accessible and scalable cancer treatments compared to autologous therapies that require manufacturing treatments from individual patients' cells. Century's pipeline includes multiple product candidates in clinical stages, though the company faces competition from established players in the CAR-T cell therapy market.
Investors are now watching for signs of stabilization in the share price and further updates on the company's clinical progress. The extended cash runway reduces near-term financing pressure, potentially allowing management to focus on advancing its therapeutic candidates rather than raising capital at unfavorable valuations.
The BMS partnership revenue surge, while impressive, may not be repeatable in future quarters, raising questions about the sustainability of the company's revenue trajectory. However, the dramatic improvement in the net loss position and strengthened balance sheet provide executives with increased flexibility as they navigate the clinical development process.